Geminii offers a wearable device that can non-invasively monitor glucose levels and respond with treatment. This device emits harmless electromagnetic waves by decreasing the blood glucose and allowing patients to manage their symptoms. The technology addresses a substantial need in a way that is unexpected and without causing substantial negative side effects. There are large companies looking to expand their diabetes portfolio and the current trends seem to indicate a healthy amount of acquisition of small companies in the space. The company will likely be able to raise funds for development from both private investors as well as national grants.